Healthcare company Baxter International (NYSE:BAX) met Wall Street's revenue expectations in Q2 CY2025, with sales up 4.3% year on year to $2.81 billion. On the other hand, next quarter's revenue ...
Is BAX a good stock to buy? We came across a bullish thesis on Baxter International Inc. on Heavy Moat Investments’s Substack. In this article, we will summarize the bulls’ thesis on BAX. Baxter ...
The utility of dominant acting proapoptotic molecules to induce cell death in cancer cells is being evaluated in preclinical studies and clinical trials. We recently developed a binary adenoviral ...
BAX Q2 revenues rose 4.3% to $2.81B but missed estimates; EPS of $0.59 missed consensus mark. BAX gross margin fell 170bps to 40.7%, pressured by product mix; operating margin rose 180bps to 15.1%.
Baxter International (BAX Quick Quote BAX - Free Report) reported $2.97 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 8%. EPS of $0.44 for the same ...
DEERFIELD, Ill., August 21, 2014 - Baxter International Inc. (NYSE:BAX) today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results